Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Score, Valuation & Financial Research

Hemab Therapeutics Holdings, Inc. Common Stock is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for COAG

Hemab Therapeutics Holdings, Inc. Common Stock does not currently have a complete Wall Street Score. The stored market price is USD 28.37. These figures are a research snapshot, not a buy or sell recommendation.

Company business and revenue

Research reporting period: 2026-06-30. A research update is not a new financial filing.

How the company makes money

Hemab Therapeutics develops investigational treatments for blood-coagulation disorders rather than selling an established portfolio of approved medicines. Its June 2026 report describes clinical and earlier-stage programs, including sutacimig and HMB-002. Development milestones are not product approvals or guaranteed future sales. Research should compare planned clinical spending with the available financing, obligations under licensing agreements and the timing of trial evidence. Fundraising proceeds are not customer revenue. The filing also describes the March 2026 reorganization of Hemab ApS under a new Delaware holding company and identifies the basis used for comparative financial statements. That relationship must be checked when interpreting historical shares and costs. The former reference to another biotechnology issuer's filing has been replaced with Hemab's own document; existing model limitations remain separate.

Products and services

  • Investigational coagulation-disorder therapies
  • Clinical and discovery-stage development programs

Business risks and research considerations

  • Clinical and regulatory uncertainty Source
  • Funding, licensing obligations and reporting comparability Source

Sources: COAG issuer disclosure: business, reporting basis and research limitations

Company research refreshed 2026-10-14. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

COAG financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 28.37
Market capitalization:
1.33B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -63.91M
Free cash flow:
USD -61.49M
Cash:
USD 237.37M
Total debt:
USD 1.03M
EPS:
USD -2.33

What stands out

  • Free cash flow is USD -61.49M, negative for the stored period.
  • The balance sheet shows USD 237.37M of cash versus USD 1.03M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a limited financial history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 236.34M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for COAG

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can COAG fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is COAG likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for COAG to reach sustainable profitability?
  • What does the current limited financial history warning mean for the reliability or interpretation of COAG's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 55% of the scoring inputs required for this public page are currently available.

How to research COAG

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.